Real-World study tracks bleeding and daily life in rare bleeding disorder
NCT ID NCT06883240
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This study observes 44 people with type 3 von Willebrand disease, a rare bleeding disorder, who are already on standard preventive treatment. Researchers will track how often bleeding episodes occur and how the condition affects quality of life over at least 24 weeks. No new drug is being tested; the goal is to gather real-world information on current care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide real-world data on how well current standard treatments control bleeding and affect daily life in type 3 VWD.
- What could go wrong
- This is an observational study, not a trial of a new treatment. It only collects existing data, so it cannot prove whether a new approach works or is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU Careggi
Florence, Tuscany, 50134, Italy
-
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, 2193, South Africa
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz
Duisburg, 47051, Germany
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Groupe Hospitalier Necker Enfants Malades
Paris, 75015, France
-
Hopital Claude Huriez - CHU Lille
Lille, 59037, France
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Hospital Universtiario Virgen del Rocio
Seville, 41013, Spain
-
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin
Frankfurt/M., 60590, Germany
-
IPS SURA Industriales Medellín
Medellín, Colombia
-
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
-
Instytut Hematologii i Transfuzjologii
Warsaw, 02-776, Poland
-
Kurume University Hospital
Fukuoka, 830-0011, Japan
-
Manchester Royal Infirmary
Manchester, M13 9WL, United Kingdom
-
McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
-
Sahlgrenska Universitetssjukhuset
Gothenburg, S-413 45, Sweden
-
St Thomas' Hospital
London, SE1 7EH, United Kingdom
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Tokyo Medical University Hospital
Tokyo, 160-0023, Japan
-
UC Davis
Sacramento, California, 95817, United States
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
Universita' Degli Studi La Sapienza-Ist.Di Ematologia
Rome, Lazio, 00161, Italy
-
University of Minnesota Medical Center
Minneapolis, Minnesota, 55455, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.